An interventional study of MAIJU and Syde in Spinal Muscular Atrophy (SMA) and Duchenne Muscular Dystrophy (DMD), sponsored by Centre Hospitalier Universitaire de Liege. Recruiting at 1 site in Belgium. Open to participants aged 4 Months and older. Per ClinicalTrials.gov, last updated 2025-12-16.
Sponsored by Centre Hospitalier Universitaire de Liege · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Muscular Atrophy, Spinal with a site in Belgium — 4 open to participants now, 10 under way, 3 of them phase 3. Muscular Atrophy, Spinal · Belgium.
Among the 26 studies in Muscular Atrophy, Spinal with a site in Belgium, this one is the 9th largest by planned enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2025, is one of 4 with no phase, and was the 24th registered.
282 studies on the registry are indexed under Muscular Atrophy, Spinal; 71 are open to participants now.
Browse Muscular Atrophy, Spinal studies →4 of the 26 studies in Muscular Atrophy, Spinal with a site in Belgium are open now. Recruiting first, the newest first:
Centre Hospitalier Universitaire de Liege · Sites in Belgium
Ages 15+
argenx · Sites in Belgium, United States, Australia and 7 more countries
Ages 5–17
Scholar Rock, Inc. · Sites in Belgium, United States, France and 4 more countries
Ages up to 2
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 56 Muscular Atrophy, Spinal studies recruiting now, 28 (50%) set no upper age limit and 25 (45%) stop at 75 or younger; 44 take children under 18; 11 take healthy volunteers.
This study: 4 Months and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 10
First in 2014; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 100 is above the median of 29 across 156 interventional studies indexed under Muscular Atrophy, Spinal.
Median enrollment 62 across the 25 interventional studies, 136,339 across the 1 observational. Of the 16 that completed or were terminated, 10 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 26 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Universitaire de Liege is the lead sponsor of 40 studies on the registry; 26 are open to participants now.
Centre Hospitalier Universitaire de Liege has 3 studies filed under Muscular Atrophy, Spinal — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 26 studies in Muscular Atrophy, Spinal with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Active NBS Liege study is a monocentric, academic, fully remote, observational study designed to validate digital measures of motor development in children with spinal muscular atrophy (SMA) or Duchenne muscular dystrophy (DMD) identified through newborn screening, family testing, or incidental diagnosis. The study will enroll 100 children and follow them longitudinally for up to 30 months. Participants are remotely recruited, and all procedures, including consent, questionnaires, and follow-up visits, are conducted by phone or video conferencing without any hospital visits. Children will use age-appropriate wearable devices at home: MAIJU®, a sensorized garment for non-ambulant infants, and Syde®, an ankle-worn sensor for ambulant children. Data collection includes digital motor endpoints, clinical information, and quality of life (PedsQL). Primary objectives are to validate digital biomarkers of motor development, while secondary objectives include early identification of motor deficits, modeling motor trajectories, and quantifying genotype-related differences. Exploratory analyses will assess gait parameters such as stride velocity 95th centile (SV95C) and compare motor outcomes across genetic profiles and treatment exposure. Risks are minimal, limited to the use of non-invasive sensors with no known side effects.
Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA) are severe, progressive, and life-limiting neuromuscular disorders that manifest during early childhood. Both conditions are characterized by motor function decline, leading to severe disability and premature mortality. The availability of disease-modifying therapies has dramatically changed the clinical landscape, but their effectiveness is strongly dependent on very early initiation, ideally before symptom onset.
Newborn screening (NBS) for SMA has now been implemented in several countries, enabling the identification of affected infants at birth. This shift creates a new challenge: the need to monitor presymptomatic or minimally symptomatic children over time with sensitive, reliable, and age-appropriate tools. Conventional motor function scales were designed for older children and are not sufficiently adapted for infants and toddlers. As a result, there is a critical gap in longitudinal assessment during the first years of life, a period when therapeutic interventions may have the greatest impact.
The Active NBS study was designed to address this unmet need. This is a monocentric, fully remote, academic, observational study that leverages wearable digital technologies to monitor motor development in very young children with SMA or DMD. The study is conducted entirely at a distance, with no requirement for hospital visits, thereby reducing the burden on families and improving accessibility.
Study Objectives:
The primary objective is to validate digital biomarkers of early motor development in children diagnosed with SMA or DMD. Secondary objectives include the early detection of motor deficits, quantification of developmental delays according to genetic subtype, and modeling of motor trajectories during the first years of life. Exploratory objectives focus on gait analysis, including stride velocity 95th centile (SV95C), and comparisons of motor outcomes across genetic backgrounds and treatment exposure.
Study Design and Procedures:
Up to 100 children will be enrolled, including infants identified by NBS, family testing, or incidental diagnosis. Enrollment and informed consent are performed remotely using secure electronic platforms. Participants are followed prospectively for up to 30 months, with assessments every 6 months through structured questionnaires and video consultations with the study team.
Two wearable devices will be employed, depending on the child's age and motor status:
Data collected include digital motor endpoints, routine clinical information, and quality of life metrics (PedsQL). Families are instructed on the correct use of devices and can install and remove them independently at home. No travel or in-person assessments are required, making this approach particularly suitable for rare disease populations.
Scientific Rationale:
Traditional motor scales, while validated in older children, lack sensitivity to detect subtle developmental changes in infancy and early childhood. Digital endpoints derived from continuous movement monitoring have the potential to provide richer, objective data on motor development. By validating these measures in a presymptomatic or early symptomatic population, this study aims to establish novel tools for both clinical practice and future interventional trials. Importantly, the study also addresses the practical and ethical challenges of long-term follow-up in very young children by implementing a fully remote design.
Expected Impact:
The Active NBS study is expected to generate the first large-scale, longitudinal dataset on motor development in presymptomatic and early symptomatic children with SMA and DMD. The validation of digital endpoints such as SV95C and BIMS will contribute to the development of sensitive outcome measures for clinical trials and may support regulatory acceptance in the future. Beyond its immediate scientific goals, the study demonstrates the feasibility and acceptability of decentralized follow-up in rare pediatric populations, setting the stage for broader applications of digital health technologies in neuromuscular disorders.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Genetically confirmed SMA and avalaible MSNA2 copy number:
Genetically confirmed DMD:
Legal guardian able to provide
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will wear a device (Maiju and/or Syde) and complete questionnaires.
Device: MAIJU · Device: Syde · Other: Questionnaires · Other: PedsQL Questionnaire
Patients will wear a device (Maiju and/or Syde) and complete questionnaires.
Device: MAIJU · Device: Syde · Other: Questionnaires · Other: PedsQL Questionnaire
A jumpsuit equipped with motion sensors for detailed assessment of motor development and postural changes. Developed by the University of Helsinki, it enables remote evaluation of infants and their motor behavior. The device has been extensively validated in healthy infants and those with cerebral palsy
The Syde® is a Class I medical device, CE-marked (compliant with European Regulation 2017/745) and manufactured by Sysnav (Vernon, France). The Syde® measures various gait parameters to assess motor abilities. It enabled the identification of SV95C in Duchenne muscular dystrophy (DMD), which became the first qualified primary endpoint in DMD, and the first digital outcome qualified by a regulatory agency. Data have been collected in about thirty DMD children under 4 years old and in an age-matched control population. These data demonstrated feasibility, reliability, and sensitivity to change in children from controls as soon as walking is acquired.
Parents will complete a specific questionnaire covering their child's medical history;
Quality-of-life questionnaire
Digital Mobility Monitoring Compliance
Measure of participant adherence to wearing the Syde® device: total recording time.
Time frame: 4 weeks of recording periods every 3 months over 2 years
Digital Mobility Monitoring Compliance
Measure of participant adherence to wearing the Syde® device: number of valid recording days (≥4 hours)
Time frame: 4 weeks of recording periods every 3 months over 2 years
Digital Mobility Monitoring Compliance
Measure of participant adherence to wearing the Syde® device: time to reach 50 and 180 hours of recording.
Time frame: 4 weeks of recording periods every 3 months over 2 years
Digital Mobility Monitoring Compliance
Measure of participant adherence to wearing the MAIJU® device using total recording time.
Time frame: 1 day of recording periods every month over 2 years
Walking Pattern Characteristics
Analysis of walking sequences: maximal walking sequence duration
Time frame: 4 weeks of recording periods every 3 months over 2 years
Walking Pattern Characteristics
Analysis of walking sequences: maximal distance walked in a single sequence.
Time frame: 4 weeks of recording periods every 3 months over 2 years
Walking Pattern Characteristics
Analysis of walking sequences: maximal 30-minute walking distance.
Time frame: 4 weeks of recording periods every 3 months over 2 years
Reliability
Inter Class Correlation (ICC2K) when comparing the first and the second half of recordings that includes more than 100 hours AND more than 2000 steps
Time frame: Baseline, 1 year, 2 years.
Group Differences in Digital Variables
Comparison of digital mobility metrics across subgroups defined by the number of SMN2 copies (SMA patients) and age's symptom appearance with 1. Patients with SMA symptoms at treatment initiation 2. Patients with 2 copies of SMN2 and no symptoms at treatment initiation 3. Patients with 3 copies of SMN2 and no symptoms at treatment initiation 4. Patients with 4 copies of SMN2 5. Healthy controls
Time frame: Age 2, 3 and 4 years
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Aug 2028, 32 months after the start.
Of 49 non-industry interventional studies with no phase under Muscular Atrophy, Spinal, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 32 months is above that.
Counting every sponsor, half of 58 studies reached it within 27 months; a quarter within 17 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de Liege